Brege Laura 4

What Happened
Laura Brege, a director of Edgewise Therapeutics, was granted 16,377 derivative securities reported as acquired at $0.00 on June 5, 2026. The filing treats these as an award/grant (not a purchase or sale); no cash was paid in the reported transaction.

Key Details

• Transaction date: June 5, 2026; Filing date: June 17, 2026 (12 days later). This appears late relative to the standard 2-business-day Form 4 reporting deadline.
• Security and amount: 16,377 derivative securities (reported as shares) at $0.00.
• Shares owned after transaction: not specified in the excerpt provided.
• Footnote: 100% of the stock options granted on June 5, 2026 will vest on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholders.
• Transaction type code: A = Award/Grant (derivative).

Context
This was a compensation-related option grant to a director. Derivative grants signal a future potential interest in company equity once vested/exercised but are not the same as an immediate purchase of stock; there is no indication the options were exercised or that any shares were sold. For retail investors, grants to insiders are routine for compensation and should be interpreted alongside other filings, vesting terms, and company developments.